A study finds an experimental adjuvant may help rebalance immune responses in people over 60, improving early antibody quality without changing overall levels.
Why it matters
As we age, our immune system changes in ways that can weaken vaccine responses—a process called immunosenescence. This is one reason older adults are at higher risk for severe flu, and why standard flu shots may not work as well in later life.
Adjuvants are ingredients added to vaccines to boost the immune response. The new LiteVax Adjuvant (LVA) is designed to do this more effectively in older adults. If it works, it could lead to flu vaccines that offer better protection for people over 60.
What the study found
In a small human study, 56 adults (18–45 and 60+) received a standard quadrivalent flu vaccine with or without LVA. Researchers tracked immune responses over time using advanced techniques like single-cell gene expression and antibody profiling.
LVA triggered a rapid, short-lived interferon-driven response in monocytes—a type of white blood cell—and enhanced interactions between dendritic cells and T cells. It also shifted flu-specific CD4+ T cells toward a memory phenotype and accelerated early IgG3 antibody responses, which are important for viral neutralization.
Notably, LVA increased IgG-producing plasmablasts without raising overall antibody levels. The authors say it reduced age-related differences in early immune responses, suggesting it may help close the gap between younger and older adults.
How to interpret this
This is a preprint, meaning it has not yet been peer-reviewed. The study is small, and the findings are mechanistic—they show how LVA affects immune markers, not whether it prevents flu or reduces severe illness.
The results are promising but preliminary. The authors note that LVA did not change overall antibody magnitude, so its benefit may be in improving response quality rather than quantity. Whether this translates into better clinical protection remains unknown.
It’s also important to remember that this is one study. More research, including larger trials and real-world effectiveness studies, is needed before any conclusions can be drawn about LVA’s value in flu vaccination.
What this means for you
For now, the practical takeaway is to continue following current flu vaccine recommendations. Standard flu shots remain the best available protection, even if they are less effective in older adults.
If you have questions about flu vaccination, talk to your healthcare provider. They can help you understand your options, including high-dose or adjuvanted vaccines that are already approved for older adults.
Keep an eye on future research about LVA and other adjuvants. This study is a step toward potentially better flu vaccines for people over 60, but it’s not a reason to change your behavior today.
Three things to remember
- LVA is an experimental adjuvant added to flu vaccines.
- Study found it improved early immune response quality.
- More research is needed before it becomes available.
Source
This analysis is based on LiteVax-adjuvanted influenza vaccine induces transient interferon-driven innate activation and accelerates early IgG3 responses in older adults from bioRxiv immunology and cell biology. Read the original report for full context.
Health note: This article is based on a preprint that has not been peer-reviewed. The findings are preliminary and do not constitute medical advice.